Compare Davita Inc (DVA) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Oatly Group AB - ADR — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Oatly Group AB - ADR trades at $12.93 (market cap $421.56M). The key difference: Davita Inc is far larger — about 27.8× Oatly Group AB - ADR's market cap. Which is the better fit depends on your goals.
| DVA | OTLY | |
|---|---|---|
Market Cap | $11.72B | $421.56M |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $18.54 |
52-Week Low | $103.87 | $8.03 |
Enterprise Value | $24.44B | $925.97M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Oatly (OTLY) trades at $13.72, up 0.22% with a bullish technical signal driven by moving averages and oversold RSI levels. Revenue growth improved to $862.46M in 2025, though net losses persist at -$152.77M. Recent Q2 2026 results beat EPS expectations, prompting a raised full-year revenue outlook to $925M, fueling a 29% stock surge on July 22, 2026 (GlobeNewsWire). The company shows progress toward adjusted EBITDA positivity, but cash burn remains a concern.
The outlook hinges on execution of margin expansion and cash flow improvement. Risks include high debt-to-asset ratio (66.53% in 2025) and intense competition. Analyst consensus is mixed with 44% buy ratings, but institutional sentiment is cautious due to profitability challenges. Upside potential exists if Oatly achieves sustained EBITDA positivity and reduces cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
